Ibutilide is the only Food and Drug Administration-approved intravenous drug for the rapid termination of atrial fibrillation and flutter. Its mechanism of action is undecided. The drug has been ...

Background: The safety and efficacy of ibutilide in the cardioversion of atrial flutter and atrial fibrillation in children and in patients with congenital heart disease (CHD) is unknown.

Although there are data to support the use of magnesium for facilitating pharmacological cardioversion, this is largely based on retrospective analyses in patients receiving ibutilide or dofetilide as ...

need for prompt restoration of sinus rhythm: DC cardioversion elective restoration of sinus rhythm: antiarrhythmic drug treatment (ibutilide or class IC agent), DC cardioversion or rapid atrial pacing ...